TY - JOUR
T1 - Pharmacoepidemiology for nephrologists (part 1)
T2 - concept, applications and considerations for study design
AU - Trevisan, Marco
AU - Fu, Edouard L
AU - Xu, Yang
AU - Jager, Kitty
AU - Zoccali, Carmine
AU - Dekker, Friedo W
AU - Carrero, Juan Jesus
PY - 2021/5
Y1 - 2021/5
N2 - Randomized controlled trials on drug safety and effectiveness are the foundation of medical evidence, but they may have limited generalizability and be unpowered to detect rare and long-term kidney outcomes. Observational studies in routine care data can complement and expand trial evidence on the use, safety and effectiveness of medications and aid with clinical decisions in areas where evidence is lacking. Access to routinely collected large healthcare data has resulted in the proliferation of studies addressing the effect of medications in patients with kidney diseases and this review provides an introduction to the science of pharmacoepidemiology to critically appraise them. In this first review we discuss the concept and applications of pharmacoepidemiology, describing methods for drug-utilization research and discussing the strengths and caveats of the most commonly used study designs to evaluate comparative drug safety and effectiveness.
AB - Randomized controlled trials on drug safety and effectiveness are the foundation of medical evidence, but they may have limited generalizability and be unpowered to detect rare and long-term kidney outcomes. Observational studies in routine care data can complement and expand trial evidence on the use, safety and effectiveness of medications and aid with clinical decisions in areas where evidence is lacking. Access to routinely collected large healthcare data has resulted in the proliferation of studies addressing the effect of medications in patients with kidney diseases and this review provides an introduction to the science of pharmacoepidemiology to critically appraise them. In this first review we discuss the concept and applications of pharmacoepidemiology, describing methods for drug-utilization research and discussing the strengths and caveats of the most commonly used study designs to evaluate comparative drug safety and effectiveness.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85122765654&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/34221367
U2 - https://doi.org/10.1093/ckj/sfaa244
DO - https://doi.org/10.1093/ckj/sfaa244
M3 - Review article
C2 - 34221367
SN - 2048-8505
VL - 14
SP - 1307
EP - 1316
JO - Clinical Kidney Journal
JF - Clinical Kidney Journal
IS - 5
ER -